GSK-2618960

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameGSK-2618960
Drug Alias NameGSK-2618960
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-7 receptor subunit alpha inhibitors
TargetsInterleukin-7 receptor subunit alpha
Therapy Area/IndicationsAutoimmune DiseasesMultiple Sclerosis, Relapsing-Remitting
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesMultiple Sclerosis, Relapsing-Remitting

Other Information

ATC CodeN/A
Related LinksN/A